Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

Table 4 MVA† of liver metastases with clinical outcome

	OS		PFS		CB
	HR (CI)	p-value	HR (CI)	p-value	OR (CI)	p-value
No liver metastases (n = 50)	0.38 (0.17–0.84)	0.017*	0.70 (0.41–1.19)	0.188	1.42 (0.39–5.21)	0.597
No liver metastases (n = 50)	Median: 21.9 months 12 month survival: 60%		Median: 3.6 months 12 month survival: 13%		Rate: 56% (0 CR, 6 PR, 22 SD, 17 PD, 5 NE)	0.026*
Liver metastases (n = 40)	Median: 8.1 months 12 month survival: 19%		Median: 1.8 months 12 month survival: 5%		Rate: 33% (1 CR, 1 PR, 11 SD, 24 PD, 3 NE)	–

MVA Multivariate analysis, OS overall survival, PFS progression-free survival, CB clinical benefit
† Covariates considered in MVA initially include age, gender, ECOG PS, prior IO, number of prior therapies, RMH risk group, race, number of metastatic sites and primary histology. Backward selection procedure was implemented by removal criterial of p > 0.05. The final controlled variables are primary histology and RMH risk group for OS and PFS and primary histology, race, and number of prior therapies for CB. MVA Multivariate analysis, OS overall survival, PFS progression-free survival, CB clinical benefit, HR Hazard Ratio, CI Confidence Interval, OR Odds Ratio
*statistical significance at alpha < 0.05 by Chi-square test

ISSN: 1471-2407